What is BioLamina?
Headquartered in Sweden, BioLamina operates at the intersection of biotechnology and clinical research. The firm specializes in the development of full-length human recombinant laminins, providing a biologically relevant matrix that significantly enhances cell functionality in both 2D and 3D environments. By offering a standardized, reproducible platform, BioLamina addresses the stringent regulatory requirements necessary for clinical compliance. Their product suite is essential for researchers and clinicians aiming to optimize cell performance and differentiation, thereby acting as a foundational element for the next generation of cell therapy and regenerative medicine breakthroughs.
How much funding has BioLamina raised?
BioLamina has raised a total of $18.2M across 1 funding round:
Other Financing Round
$18.2M
Other Financing Round (2023): $18.2M with participation from Lauxera Capital Partners
Key Investors in BioLamina
Lauxera Capital Partners
Lauxera Capital Partners is an independent, international investment fund that focuses on growth companies in the Healthtech sector, partnering with world-class managers to enhance efficiency and innovation in medical devices and diagnostics.
What's next for BioLamina?
With this major enterprise-level funding, BioLamina is poised to scale its operational capacity and expand its footprint in the global life sciences market. The strategic roadmap likely involves deepening its R&D pipeline to support more complex cell therapy workflows and enhancing its manufacturing capabilities to meet the growing demand for clinical-grade reagents. As the industry shifts toward more sophisticated regenerative treatments, BioLamina's focus on high-performance matrices positions it as a key enabler for therapeutic innovation. The company will likely prioritize commercial expansion and regulatory scaling to maintain its competitive edge in the rapidly evolving biotechnology landscape.
See full BioLamina company page
